Catalyst Oncology

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today the publication of a preclinical study describing the synthesis and initial evaluation of two series of radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer. The lead compounds, MIP-1072 and MIP-1095, demonstrated high affinity and specific binding to PSMA on human prostate cancer cells, and the radiolabeled analogs provide the foundation for the

Go here to read the rest: 
Two Compounds In The Trofex™ Prostate Cancer Molecular Imaging Program Specifically Target Prostate Cancer Cells